2020
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map
Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews 2020, 42: 100706. PMID: 32517877, DOI: 10.1016/j.blre.2020.100706.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic myeloid leukemiaPolycythemia veraEssential thrombocythemiaMyeloproliferative neoplasmsClassical myeloproliferative neoplasmsPrimary myelofibrosisIncidence of CMLEnd Results program dataTyrosine kinase inhibitor therapyCML patient outcomesClonal myeloid disordersKinase inhibitor therapyPotential etiological roleInhibitor therapyMale genderRisk factorsPatient outcomesMyeloid leukemiaPMF patientsBetter survivalGeneral populationEtiological roleMyeloid disordersMolecular abnormalitiesEpidemiological literature
2018
Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it
Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews 2018, 34: 1-15. PMID: 30314642, DOI: 10.1016/j.blre.2018.09.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCase ascertainmentAllogeneic hematopoietic stem cell transplantationAnnual age-adjusted incidenceHematopoietic stem cell transplantationOutcomes of patientsAge-adjusted incidenceStem cell transplantationAcute myeloid leukemiaTraditional morphologic assessmentClassification of MDSVariable cytopeniasCell transplantationMyelodysplastic syndromePrior receiptInefficient hematopoiesisEffective therapyMale genderRisk factorsMyeloid leukemiaEpidemiological trendsTreatment decisionsMyeloid neoplasmsEpidemiological assessmentDiagnostic criteriaTemporal improvementSelection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States
Ma X, Steensma DP, Scott BL, Kiselev P, Sugrue MM, Swern AS. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. BMJ Open 2018, 8: e019955. PMID: 30037860, PMCID: PMC6059277, DOI: 10.1136/bmjopen-2017-019955.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnemiaAzacitidineDatabases, FactualDecitabineElectronic Health RecordsEnzyme InhibitorsFemaleHematinicsHumansImmunologic FactorsIron Chelating AgentsLenalidomideMaleMiddle AgedMultivariate AnalysisMyelodysplastic SyndromesProportional Hazards ModelsRecurrenceRetrospective StudiesThalidomideTreatment OutcomeUnited StatesConceptsDisease-modifying therapiesErythropoiesis-stimulating agentsElectronic medical record databaseMyelodysplastic syndromeMedical record databasePatient characteristicsTreatment patternsGE Centricity Electronic Medical Records databaseRecord databaseLow baseline hemoglobin levelMultivariable Cox regression modelsLarge electronic medical record databaseBaseline hemoglobin levelAbsence of comorbiditiesFirst-line treatmentMajority of patientsSelection of patientsCox regression modelIron chelation therapyAgent azacitidineMore comorbiditiesHemoglobin levelsMale genderClinical trialsChelation therapy